Jump to content

Semuloparin sodium

From Wikipedia, the free encyclopedia
Semuloparin sodium
Clinical data
Other namesAVE-5026
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
ECHA InfoCard100.110.590 Edit this at Wikidata
Chemical and physical data
Molar mass2000–3000 g/mol (average)

Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH).[1] It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement,[2] as well as for patients undergoing chemotherapy.[3]

Like bemiparin, semuloparin is classified as an ultra-LMWH because of its low molecular mass of 2000–3000 g/mol on average. (Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.[4][5]

References

[edit]
  1. ^ Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E (February 2011). "New parenteral anticoagulants in development". Therapeutic Advances in Cardiovascular Disease. 5 (1): 33–59. doi:10.1177/1753944710387808. PMID 21045018. S2CID 36442831.
  2. ^ Clinical trial number NCT00697099 for "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery (SAVE-HIP1)" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT00694382 for "Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)" at ClinicalTrials.gov
  4. ^ Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, et al. (October 2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin". Thrombosis Research. 128 (4): 361–7. doi:10.1016/j.thromres.2011.03.001. PMID 21458847.
  5. ^ Statement On A Nonproprietary Name Adopted By The Usan Council: Semuloparin Sodium